Objective To assess the effect of treatment on limiting weight gain in abstainers using and not using varenicline and during the nontreatment phase.
Introduction
Tobacco use may cause cancer, heart disease, and chronic obstructive pulmonary disease, and is associated with high rates of mortality worldwide each year, with 5-6 million people dying of smoking-related diseases. 1, 2 Relative to nonsmokers, smokers lose at least 10 years' life expectancy. 3 Several strategies are available for smoking cessation, including counselling, social support and several pharmacotherapies. 4 However, most smokers who try to quit smoking ultimately relapse, and the rate of successful smoking cessation has been found to be very low. 5 In addition to nicotine dependence and abstinence syndrome, weight gain is one of the most important reasons that smoking cessation may be unsuccessful. 6, 7 One study showed that nicotine may affect the molecular target in the brain for appetite suppression, causing smokers to eat less, which then contributes to weight maintenance or reduction. 8 Especially among female smokers, weight gain is the primary obstacle to quitting smoking and cause of relapse after cessation. 9 In the United States, smoking cessation has even become a crucial reason for the high prevalence of overweight and obesity. 10 Therefore, preventing weight gain after smoking cessation is important for both cognitive selfcontrol manipulation of smoking behaviours and the prevention of diseases associated with weight gain after smoking cessation. Varenicline was approved by the US Food and Drug Administration in 2006 as a prescription medicine for smoking cessation, 11 and, has been identified as the most effective medication for smoking cessation on the market. 12 Many previous studies have focused on weight gain after smoking cessation using varenicline, but only a few studies have provided detailed results including means and standard deviations (SDs) for weight change. A Cochrane review showed that three treatments, nicotine replacement therapy, bupropion and varenicline, reduced weight gain among abstainers during 6 months' follow-up by 0.5, 1.1 and 0.4 kg, respectively. 13 In addition, in a study conducted by Taniguchi et al., 14 varenicline was found to be more effective in attenuating weight gain than the nicotine patch in smokers who received Japanese smoking cessation therapy. However, in another two studies, a greater amount of weight was gained in the group taking varenicline than the placebo group during smoking cessation therapy. 15, 16 Obviously, the results regarding this subject have been conflicting.
Thus, the aim of the study was to assess the effect of treatment on limiting weight gain in abstainers using varenicline and not using varenicline during the nontreatment period.
Method Search strategy
Study selection was completed by all authors. We searched the PubMed, Medline, EMBASE and Cochrane Library databases to identify articles published in English and Chinese, and the search items included 'smoking cessation' or 'quit smoking' and 'varenicline' or 'Chantix' or 'Champix' and 'weight gain' in various combinations. Because Varenicline was made available in the US market-place in 2006, the databases were searched for studies published from 2006 to 2016. Furthermore, we reviewed the reference lists of the retrieved studies to identify additional studies that were not captured by our database searches.
A flow diagram illustrating the details of our study selection process is provided in Fig. 1 ; overall, 678 studies were identified during the literature search, and all abstracts were reviewed. A total of 532 articles were excluded because their abstracts indicated that the study failed to meet the inclusion criteria or met the exclusion criteria. Finally, 10 of the 146 eligible studies including one cohort study 14 and nine randomized control trials (RCTs), [15] [16] [17] [18] [19] [20] [21] [22] [23] were included in the metaanalysis after full-text reviews, all of which provided weight data.
Inclusion criteria
Two investigation assessed the full text of every identified study to ensure the study was eligible for inclusion in this meta-analysis. The inclusion criteria were as follows: (i) RCT or cohort study, (ii) exposure of interest was taking varenicline, (iii) outcome of interest was weight gain, (iv) reported data on weight change from baseline to follow-up points in abstainers, (v) reported the results as means and SDs of weight change and (vi) weights were determined based on clinical data.
Exclusion criteria
The exclusion criteria were as follows: (i) animal and in vitro studies; (ii) reviews, comments and editorials; and (iii) studies using other research designs.
Data extraction and quality assessment
The data extracted by two investigators from each study were as follows: first author name, publication year, study duration, region, treatments used, member of patients at baseline, proportion of women at baseline (%), mean age at baseline, mean cigarette intake at baseline, and mean and SD of weight change in abstinent smokers only. Of the 10 studies, two 20, 21 included multilevel dose groups. In the remaining eight studies, the subjects usually received 2 mg varenicline per day during the treatment phase; therefore, we ultimately included the use of a dosage of 2 mg per day within inclusion criteria. Moreover, in the study conducted by Taniguchi's VARENICLINE IS ASSOCIATED WITH A MODEST LIMITATION e127 study, 14 the authors reported mean weight change data multiple times; for this study, we only extracted data for the end of treatment and the last report. In cases of disagreement between the two investigators, consensus was reached via discussion among the authors. The nine-star Newcastle-Ottawa Scale 24 was used to determine the quality of the cohort studies and Jadad scores 25 were used to determine the quality of RCTs.
Statistical analysis
We pooled the obtained data to describe weight changes in abstainers treated with varenicline and controls. We measured heterogeneity using the I 2 statistic. When high heterogeneity (I 2 > 50%) was identified across studies, a random effects model (REM) (the inverse variance heterogeneity method) was adopted to calculate weighted mean differences (WMDs) for weight change; otherwise, fixed effect models (FEMs) were used. A sensitivity analysis was carried out by sequentially omitting studies using I 2 > 50% as the criterion to identify key studies with a substantial impact on betweenstudy heterogeneity. 26 We conducted an influence analysis to determine the robustness of the pooled estimate after the removal of individual studies. We used Egger's regression asymmetry test to detect any publication bias. 27 All statistical analyses were performed using STATA version 13.1 (Stata Corporation, College Station, TX, USA). All reported probabilities (P-value) were two-sided, and P < 0.05 was considered statistically significant.
Results

Study characteristics
A total of 10 studies were included in this meta-analysis; within these studies, 1230 abstainers used varenicline and 759 abstainers used another treatment. All studies recruited both males and females. The general characteristics of the included studies are shown in Table 1 . Of the 10 included studies, seven were from Europe or the USA, [15] [16] [17] [18] 21, 22, 28 and three studies were from Asia. 14, 20, 23 Two studies 14, 22 reported weight gain at two points (12 and 52 weeks or 12 and 60 weeks); for these studies, we extracted data for both points.
Effect on weight gain
Figs 2 and 3 show the WMDs in weight gain in smokers after smoking cessation between the varenicline and control groups and their corresponding 95% CIs (WMD = −0.23 kg, 95% CI: −0.36 to −0.09, P < 0.05). The results indicated that taking varenicline and the control therapy both resulted in increased weight in the abstainers. Compared with the control therapy, varenicline was associated with 0.23 kg less weight gain. In the subgroup analysis by timepoint of weight measurement, the results illustrated that the WMD in weight gain in abstainers between varenicline and control groups in the 12-week treatment phase was −0.23 kg (95% CI: −0.37 to −0.08, P < 0.05), and the WMD in the nontreatment follow-up phase was −0.69 kg (95% CI: −2.15 to 0.77, P > 0.05); thus, in the 12-week treatment phase, a significant difference in weight gain was observed. In the control group, we first classified controls into groups defined by those receiving placebo and those receiving another treatments. The result showed that the WMD in weight gain in abstainers between the varenicline and placebo groups was −0.29 kg (95% CI: −0.46 to −0.12, P < 0.05), and the WMD between those receiving varenicline and those receiving another control treatment was −0.20 kg (95% CI: −0.77 to 0.37, P > 0.05); within this analysis, significant difference was observed between the varenicline and placebo groups. Moreover, we also performed a sensitivity analysis to identify the sources of heterogeneity across studies overall and by subgroup. All results are shown in Table 2 .
Sensitivity analysis
To find the source of heterogeneity across studies of weight gain in smokers after smoking cessation with varenicline and those who went untreated, a sensitivity analysis was performed by sequentially removing studies overall and within the subgroups (I 2 > 50%). In addition, a study conducted by Tsai et al. 23 was found to be the one of the main factors responsible for between-study heterogeneity in this metaanalysis. After excluding that study, the results remained significant (Table 2) .
Influence and publication bias analysis
We did not identify any study to have a significant influence on the pooled effect estimate both before and after excluding studies contributing to between-study heterogeneity. Furthermore, significant publication bias was not identify in this meta-analysis, as indicated using Egger's regression asymmetry test.
Discussion Main findings of this study
Our meta-analysis of 10 studies showed the WMD in weight gain in smokers after smoking cessation between the varenicline and control groups (WMD = −0.23 kg, 95% CI: −0.36 NRT = transdermal nicotine replacement therapy; NR = non-report. Healthy smokers were defined as smokers motivated to quit smoking who did not have a serious or unstable disease, such as mental illness, severe chronic obstructive pulmonary disease, a history of cancer and clinically significant allergic reactions. NP = nicotine patch; ex-smokers with NRT were defined as smokers who reported long-term (>11 months) abstinence from daily smoking, were current users of flexible-dose NRT and were willing to try to stop using NRT. 'a' and 'b' refer to two separate studies reported in the same article.
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to −0.09, P < 0.05). Although smoking cessation has been widely recognized to lead to weight gain, this meta-analysis contributes to the argument that taking varenicline may limit weight gain after smoking cessation; however, the observed limitation of weight gain was small. In fact, the observed limitation did not differ from the effect of placebo treatment (which was also statistically but not clinically significant). Moreover, this modest limitation did not last and became non-significant during nontreatment follow-up (52 weeks or more).
What is already known on this topic?
The mechanism of weight gain after smoking cessation may be complex. Previous studies have reported that weight gain after smoking cessation was associated with increased energy intake, decreased resting metabolic rate, decreased physical activity and increased lipoprotein lipase activity. [29] [30] [31] However, a neurobiological study 32 reported that activation of pro-opiomelanocortin (POMC) neurons is the mechanism by which nicotine decreases food intake. The activation of POMC neurons contributes to the activation of hypothalamic α3β4 nicotine acetylcholine receptors. According to that study, the hypothalamic melanocortin system had been identified as critical molecular and synaptic mechanisms involved in nicotine-induced decreases in food intake and body weight after smoking or nicotine intake. 32 This mechanism might be the reason that abstainers have been found to lose weight after relapse and became leaner. 29 Weight gain is nearly unavoidable after smoking cessation. A cohort study using data from over eight years reported that the average weight gain after this time period of smoking cessation was 8.79 kg. 33 A meta-analysis of 62 studies about weight gain after smoking cessation reported mean weight gains of 2.12 and 2.85 kg after 3 months' abstinence and 4.17 and 4.67 kg after 12 months' abstinence in varenicline users and untreated abstainers, respectively. 34 Meanwhile, we also found that weight gain was similar between those using varenicline and those receiving placebo treatment following the same abstinence period. Therefore, the result of that meta-analysis provide strong evidence supporting our results.
What this study adds
Studies were required to be randomized controlled trials or cohort study assessing smoking cessation and utilizing interventions (varenicline) to prevent weight gain for inclusion in this meta-analysis. The frequency of follow-up and record of abstinence indicate that the data for weight gain were valid.
However, there have been many studies on the effect of smoking cessation using varenicline, and few studies have included data on the mean and SD of weight change. In the included studies, variations in mean weight gain across studies were one of the main factors leading to high heterogeneity.
The results of our meta-analysis have clinical implications. In practice, doctors could inform abstainers in advance that varenicline may modestly limit their weight gain during abstinence from smoking and help them to control their weight or intervene early to prevent weight gain in other ways. 
e130 JOURNAL OF PUBLIC HEALTH
Limitations of this study
Unlike other smoking cessation medications, varenicline has demonstrated greater efficacy in terms of short and immediateterm outcomes in female smokers. 35 Unfortunately, in our meta-analysis, we were unable to identify a significant difference of weight changes between genders. We solely obtained information about women at baseline; however, we could only extract the proportion of female abstainers in the study conducted by Taskkin et al., 16 and data for weight gain were not classified by gender in this study. Moreover, the mean and SD of weight change among women were also not readily obtainable from these studies.
The participants of these included studies were smokers or ex-smokers treated in clinics for smoking dependence. These participants were heavier smokers than the general population of smokers, and evidence regarding whether heavier smokers or general smokers gain more weight or general smokers gain more weight is conflicting. 36 Moreover, only 10 studies were ultimately included in this meta-analysis. Sterne et al. suggested that meta-analysis including 10 or fewer studies may have limited power to detect publication bias (small-study effect). 37 
Conclusion
In conclusion, the result of our meta-analysis suggested that varenicline was associated with a modest limitation in weight gain in smokers after smoking cessation, but this difference was not different from the observed placebo effect which was also statistically but not clinically significant and even this small effect did not last long. Further studies are needed to confirm these conclusions. 
